{
    "pmcid": "8651292",
    "qa_pairs": {
        "How were the nanobodies against the SARS-CoV-2 spike protein generated in the study?": [
            "Through llama immunization and affinity purification of VHH domains.",
            "By synthesizing them from human monoclonal antibodies.",
            "Using computational modeling to predict optimal binding sequences.",
            "By extracting them from convalescent human plasma."
        ],
        "What is a key advantage of nanobodies derived from camelids in targeting SARS-CoV-2?": [
            "Their small size allows them to bind to otherwise inaccessible epitopes.",
            "They have a higher molecular weight compared to traditional antibodies.",
            "They are derived from the light chain of antibodies, enhancing their binding specificity.",
            "Their large size enables them to cover multiple epitopes simultaneously."
        ],
        "What is one mechanism by which nanobodies neutralize SARS-CoV-2?": [
            "Direct competition with ACE2, preventing viral entry.",
            "Enhancing the viral replication process to induce rapid mutation.",
            "Binding to the viral RNA to inhibit transcription.",
            "Blocking the viral envelope proteins from assembling."
        ],
        "What method was used to determine the kinetic properties of the selected nanobodies?": [
            "Surface plasmon resonance (SPR).",
            "X-ray crystallography.",
            "Nuclear magnetic resonance (NMR) spectroscopy.",
            "Cryo-electron microscopy."
        ],
        "What strategy was employed to enhance the neutralization potency of nanobodies?": [
            "Rational combinations of nanobodies binding distinct sites showed extraordinary synergy.",
            "Increasing the dosage of a single nanobody to achieve higher concentrations.",
            "Using chemical modifications to increase their molecular weight.",
            "Targeting only the RBD region to maximize binding affinity."
        ]
    }
}